Trevena, Inc. TRVN

TRVN Company Overview

Trevena, Inc. is a clinical-stage and commercial biopharmaceutical company focused on developing and commercializing medicines that target G protein-coupled receptors (GPCRs). The company operates primarily within the biotechnology and pharmaceutical industries, with a concentration on neuroscience, pain management, and central nervous system disorders. Trevena is best known for developing OLINVYK (oliceridine), an intravenous opioid analgesic approved in the United States for the management of acute pain severe enough to require an intravenous opioid when alternative treatments are inadequate. The company has also advanced investigational therapies for conditions including epilepsy and other neurologic disorders through its GPCR pathway-focused research platform.

The company’s core revenue drivers have historically included product sales, licensing arrangements, collaborative agreements, and milestone-related payments tied to development partnerships. Trevena’s strategic positioning has centered on its expertise in biased ligand technology designed to selectively activate therapeutic signaling pathways while potentially reducing adverse effects associated with traditional receptor activation. Founded in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena evolved from a research-focused biotechnology company into a commercial-stage organization following the FDA approval of OLINVYK in 2020.